No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NWBO Northwest Biotherapeutics
- 0.415000
- +0.005000+1.22%
15min DelayClose Jul 2 16:00 ET
502.51MMarket Cap-5928P/E (TTM)
0.428000High0.402100Low1.18MVolume0.408000Open0.410000Pre Close486.84KTurnover0.11%Turnover RatioLossP/E (Static)1.21BShares1.09000052wk High-6.80P/B456.50MFloat Cap0.39500052wk Low--Dividend TTM1.10BShs Float112.000000Historical High--Div YieldTTM6.32%Amplitude0.140000Historical Low0.413000Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Northwest Biotherapeutics | 10-Q: Quarterly report
Northwest Biotherapeutics Appoints Pat Sarma as Class II Director
Northwest Biotherapeutics Board Veteran Jasinowski Retires
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
The Company believes that the Flaskworks system will play a central role in enabling the efficient and timely scale-up of manufacturing to make DCVax-L products for large numbers of patients, and in reducing the manufacturing facility costs.
Northwest Biotherapeutics Submits Marketing Authorization Application to UK MHRA for DCvax
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma
Northwest Biotherapeutics (OTCQB: NWBO) announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax-L for glioblastoma brain cancer.
Comments
$Northwest Biotherapeutics(NWBO.US$ Long-Term Survival: The “long tail” of the survival curve showed that more than double the patients survived longer than those treated with the standard of care, highlighting the potential for long-term benefits.
Safety Profile: DCVax-L exhibited a benign safety profile, with adverse events not meaningfully different from the standard of care. This is particularly important as it means the therapy can be administered with fewer concerns about severe side eff...
Safety Profile: DCVax-L exhibited a benign safety profile, with adverse events not meaningfully different from the standard of care. This is particularly important as it means the therapy can be administered with fewer concerns about severe side eff...
$Northwest Biotherapeutics(NWBO.US$ Northwest Biotherapeutics Inc. (NWBO) is making progress towards regulatory approval for its DCVax®-L treatment for glioblastoma. They have submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. This submission is a significant step, but it indicates that approval is still pending
$Northwest Biotherapeutics(NWBO.US$ Northwest Biotherapeutics Inc. (NWBO) has been involved in significant legal actions related to allegations of stock manipulation. The company has accused several defendants, including Citadel Securities, associated with Ken Griffin, of “spoofing” to manipulate NWBO’s stock price between 2017 and 2022. Spoofing involves placing orders to create the illusion of demand or supply, thus affecting the stock price and harming NWBO’s valuation. Ken Griffin and Citad...
$Northwest Biotherapeutics(NWBO.US$ Northwest Biotherapeutics Inc. (NWBO) has made several significant moves recently. The company secured an exclusive license for advanced dendritic cell technologies from Roswell Park Comprehensive Cancer Center. This includes five new patent families with technologies currently in Phase 2 clinical trials for two cancers, and a third Phase 2 trial pending. This development aligns with NWBO’s strategy to enhance its portfolio and advance personalized immune the...
$Northwest Biotherapeutics(NWBO.US$ Diamond hands
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg